The Alliance NCTN Biorepository and Biospecimen Resource

NCTN 生物样本库和生物样本资源联盟

• 批准号: 10226354
• 负责人: Mine Cicek
• 金额: $ 330.83万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-19 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10226354
• 关键词: Advanced Malignant Neoplasm; Affect; Automobile Driving; Biological; Biological Assay; Biological Markers; Biological Specimen Banks; Cancer Control; Cancer Diagnostics; Clinical; Clinical Research; Clinical Trials; Collection; Communities; Community Clinical Oncology Program; Companions; Data; Eligibility Determination; Enrollment; Equipment and supply inventories; Future; Genomics; Image; Immunologic Monitoring; Informatics; Infrastructure; Laboratories; Leadership; Liquid substance; Malignant Neoplasms; Methods; Mission; National Clinical Trials Network; Oncology; Pathology; Patients; Prevention trial; Procedures; Process; Proteomics; Research; Resources; Science; Services; Site; Slide; Speed; Stratification; Techniques; The Cancer Genome Atlas; Therapeutic Trials; Time; Tissues; Translational Research; Translations; Work; anticancer research; base; biobank; biomarker development; biomarker validation; cancer clinical trial; candidate marker; clinical practice; cohort; community setting; control trial; cost; digital; improved; innovation; liquid biopsy; meetings; member; minimally invasive; multidisciplinary; new technology; novel; operation; programs; prospective; quality assurance; single cell sequencing; targeted treatment; tool; translational cancer research; treatment trial; trial design; tumor; validation studies

PROJECT SUMMARY/ABSTRACT The NCTN's Alliance for Clinical Trials in Oncology (Alliance) and its associated biorepositories represent an unequaled resource of expertise, institutional infrastructure, and high quality, densely annotated patient biospecimens collected from several decades of cancer therapeutic trials. The scientific mission of the Alliance Biorepository and Biospecimen Resource (ABBR) is to support the activities of the Alliance, the NCTN, and the broader cancer research community through four specific aims, which are: 1) To prospectively support Alliance and NCTN-wide clinical cancer trials with respect to biospecimen procurement, tracking, processing, quality assurance, storage, and distribution. The ABBR implements a number of innovative approaches to streamline biospecimen collection and support the collection of novel biospecimen types for genomic, proteomic, immunoncology, and `liquid biopsy' biomarker studies in the context of therapeutic trials; 2) To provide a resource of high quality, densely annotated biospecimens for secondary correlative science studies directed toward biomarker validation with high clinical impact. The ABBR cooperates with other NCTN biorepositories, the NCTN Biospecimen `Front Door Service', and the NCTN Navigator tool to provide inventories of biospecimens that may be suitable for secondary correlative science studies proposed both within the NCTN groups as well as the broader cancer research community. It also works with other NCTN members and NCI to create an efficient and transparent process for reviewing, approving, and executing such requests so as to speed the translation of candidate biomarkers to cancer diagnostics with clinical utility; 3) To provide scientific leadership to the NCTN biobanking enterprise, by active participation in the NCTN Group Banking Committee (GBC). The ABBR will continue its outstanding commitment to harmonizing and improving biobanking Best Practices by active participation in GBC meetings, subcommittees activities, and work products, and; 4) To provide expertise and infrastructure support for biobanking efforts aligned with and beyond the NCTN, including the Cancer and Immune Monitoring Analysis Centers (CIMACs) and the Community Oncology Research Program (NCORP). Having created a federated infrastructure of biorepository sites and a unifying informatics platform for tracking biospecimens across them, the ABBR continues to be uniquely poised to collaborate with other NCI programs, whenever biorepository or biospecimen resources are required for specific translational cancer research efforts.

项目摘要/摘要 NCTN的肿瘤学临床试验联盟（联盟）及其相关的生物敏化代表 专业知识，机构基础设施和高质量，密集注释的患者的资源无与伦比的资源 从几十年的癌症治疗试验中收集的生物菌群。科学任务的 联盟生物座席和生物循环资源（ABBR）是为了支持联盟的活动， NCTN和更广泛的癌症研究界通过四个特定目标，即：1） 前瞻性支持联盟和NCTN范围内的临床癌试验 采购，跟踪，处理，质量保证，存储和分配。 ABBR实施 精简生物循环收集并支持小说的创新方法数量 用于基因组，蛋白质组学，免疫学和“液体活检”生物标志物研究的生物循环类型 治疗试验的背景； 2）提供高质量，密集注释的生物测量资源 二级相关科学研究针对生物标志物验证具有很高的临床影响。这 ABBR与其他NCTN生物座席合作，NCTN Biospecimen“前门服务”和 NCTN导航器工具可提供可能适合二级相关性的生物测量清单 科学研究提出了NCTN组内以及更广泛的癌症研究界。 它还可以与其他NCTN成员和NCI一起使用，以创建一个高效且透明的过程 审查，批准和执行此类请求，以加快候选生物标志物的翻译 进行临床实用性的癌症诊断； 3）为NCTN生物库提供科学领导 企业，通过积极参与NCTN集团银行委员会（GBC）。 ABBR将继续 它致力于通过积极参与来协调和改善生物群的最佳实践的杰出承诺 在GBC会议，小组委员会活动和工作产品中，以及； 4）提供专业知识和 基础设施支持与NCTN以及包括癌症和包括癌症和之外的生物库的基础设施 免疫监测分析中心（CIMAC）和社区肿瘤研究计划 （ncorp）。创建了生物座位站点的联合基础架构和一个统一的信息学 跟踪它们之间的生物测量的平台，ABBR继续唯一准备合作 对于其他NCI计划，每当需要特定的生物座位或生物测量资源时 转化癌症研究工作。